Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (91-100 of 490) with videos related to

Pageof 49
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim MelanomIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
International Journal of Cancer|July 19, 2002
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patientsVera Rebmann, Selma Ugurel, Wolfgang Tilgen, et al.
European Journal of Dermatology : EJD|August 29, 2006
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanomaAdina Thoelke, Hans-Peter Schmid, Robert Figl, et al.
Cancer Treatment and Research|October 24, 2007
New promises in the adjuvant, and palliative treatment of melanomaAxel Hauschild, Dirk Schadendorf, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update on the clinical use of kinase inhibitors in melanomaIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
The Interplay between Metabolic Adaptations and Diet in Cancer ImmunotherapyLena Espelage, Natalie Wagner, Jan-Malte Placke, et al.
Expert Opinion on Therapeutic Targets|October 28, 2018
Targeting SOX2 in anticancer therapyLaura Hüser, Daniel Novak, Viktor Umansky, et al.
Stem Cells (Dayton, Ohio)|July 19, 2008
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expressionSarah Eminli, Jochen Utikal, Katrin Arnold, et al.
Science (New York, N.Y.)|September 27, 2008
Induced pluripotent stem cells generated without viral integrationMatthias Stadtfeld, Masaki Nagaya, Jochen Utikal, et al.
Cancers|January 8, 2020
STAT3 Relays a Differential Response to Melanoma-Associated <i>NRAS</i> MutationsJames Kim, Daniel Novak, Christos Sachpekidis, et al.
Pageof 49

Showing results (91-100 of 490) with videos related to

Sort By:
Pageof 49
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim MelanomIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
International Journal of Cancer|July 19, 2002
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patientsVera Rebmann, Selma Ugurel, Wolfgang Tilgen, et al.
European Journal of Dermatology : EJD|August 29, 2006
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanomaAdina Thoelke, Hans-Peter Schmid, Robert Figl, et al.
Cancer Treatment and Research|October 24, 2007
New promises in the adjuvant, and palliative treatment of melanomaAxel Hauschild, Dirk Schadendorf, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update on the clinical use of kinase inhibitors in melanomaIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
The Interplay between Metabolic Adaptations and Diet in Cancer ImmunotherapyLena Espelage, Natalie Wagner, Jan-Malte Placke, et al.
Expert Opinion on Therapeutic Targets|October 28, 2018
Targeting SOX2 in anticancer therapyLaura Hüser, Daniel Novak, Viktor Umansky, et al.
Stem Cells (Dayton, Ohio)|July 19, 2008
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expressionSarah Eminli, Jochen Utikal, Katrin Arnold, et al.
Science (New York, N.Y.)|September 27, 2008
Induced pluripotent stem cells generated without viral integrationMatthias Stadtfeld, Masaki Nagaya, Jochen Utikal, et al.
Cancers|January 8, 2020
STAT3 Relays a Differential Response to Melanoma-Associated <i>NRAS</i> MutationsJames Kim, Daniel Novak, Christos Sachpekidis, et al.
Pageof 49